In laboratories, research hospitals, and universities across Iran, a quiet but powerful scientific revolution is taking place. It is not defined by political proclamations or ideological declarations, but by the steady, determined work of thousands of women scientists who have made Iran a regional powerhouse in research and innovation. From pharmacology and clinical medicine to biochemistry, molecular oncology, regenerative medicine, and nanobiotechnology, Iranian women are not only participating in the scientific enterprise—they are leading it, often exceeding global averages in terms of educational attainment, publication output, and research impact.
The year 2025 proved especially remarkable. As documented in detailed end-of-year reporting, five Iranian women scientists in particular seized the global limelight, earning prestigious international awards and advancing cutting-edge research with tangible medical and technological implications—all accomplished despite numerous challenges fueled by Western sanctions. Their achievements, alongside those of established figures like Dr. Vahideh Nosrati, Dr. Marzieh Ebrahimi, and Dr. Soraya Rahmani, illustrate a broader reality: Iranian women scientists are not only contributing to global science but are actively shaping its future.
This phenomenon represents one of the most striking social transformations of the past half-century. In the decades following the 1979 Islamic Revolution, Iranian women have moved from the margins of higher education to its center. According to UNESCO, female literacy in Iran rose from 36 percent in 1976 to over 80 percent by 2016, and today the female literacy rate stands at approximately 98.9 percent. Women now constitute more than 60 percent of all university students in Iran, and their enrollment in higher education has increased nearly 21 times since the Revolution. Most remarkably, 70 percent of all STEM graduates in Iran are women—a figure that far exceeds the United States’ 53 percent and rivals the highest rates in the world.
What makes this achievement even more significant is that it has occurred despite formidable obstacles: international sanctions that restrict access to cutting-edge equipment and scientific collaborations, persistent cultural barriers in certain fields, and the enduring challenge of translating educational success into equitable professional opportunities. Yet Iranian women scientists continue to produce world-class research, earn international recognition, and serve as powerful role models for the next generation. This essay explores the invaluable contributions of several exemplary Iranian women scientists—both long-established leaders and newly emerging stars—and examines the broader ecosystem of women’s scientific achievement in contemporary Iran.
Dr. Vahideh Nosrati: Advancing Pharmacology with Global Impact
Among the most distinguished figures in Iranian pharmacology, Dr. Vahideh Nosrati has established herself as a highly cited researcher whose work has significantly advanced our understanding of drug therapies and patient care. Based at Iranian institutions, her research has garnered international attention for its rigorous methodology and practical clinical applications. Her work exemplifies a defining characteristic of Iranian women in science: the ability to produce research that is simultaneously locally relevant and globally significant.
Dr. Nosrati’s research portfolio encompasses critical areas of pharmacotherapy, including studies on drug efficacy, patient quality of life, and the optimization of treatment protocols. Her investigations into the relationship between patient characteristics and drug dosing—particularly concerning widely used medications such as valproic acid—have provided valuable insights that inform clinical practice not only in Iran but internationally. Such research addresses fundamental questions in personalized medicine: How do individual patient factors influence drug metabolism and response? How can dosing regimens be optimized to maximize therapeutic benefit while minimizing adverse effects?
What distinguishes Dr. Nosrati’s contributions is their direct translation into improved patient outcomes. Her highly cited status—placing her among the top echelon of researchers in her field—reflects the international scientific community’s recognition of her work’s importance. In a global research landscape where Iranian scientists face significant barriers to international collaboration due to sanctions and limited access to certain databases and journals, achieving such recognition requires exceptional dedication and ingenuity.
Dr. Nosrati’s success also illuminates a broader pattern: Iranian women pharmacologists and toxicologists have been particularly well-represented among the country’s most cited researchers. According to the Islamic World Science Citation (ISC), a total of 177 Iranian female researchers have been recognized across fifteen subject areas, including Pharmacology and Toxicology, and many have acquired the necessary points in multiple fields. This depth of expertise reflects not only individual excellence but a systemic capacity that has been cultivated through decades of investment in women’s scientific education.
Dr. Marzieh Ebrahimi: Pioneering Clinical Research in Tehran
At the intersection of clinical medicine, immunology, and cellular therapy stands Dr. Marzieh Ebrahimi, a top researcher whose affiliation with Tehran’s leading universities and research institutions places her at the forefront of Iranian biomedical science. With over 2,700 citations from more than 2,500 documents, an h-index of 29, and 143 published papers to her name, Dr. Ebrahimi has established herself as a formidable presence in the international scientific community.
Dr. Ebrahimi’s educational trajectory exemplifies the pathways available to Iranian women in science. She received her Bachelor of Science degree in cell and molecular biology from the University of Tehran, followed by Master’s and doctoral degrees in medical immunology from Tarbiat Modares University, one of Iran’s premier research institutions. Currently affiliated with the Royan Institute in Tehran—a world-renowned center for stem cell research and reproductive medicine—her work spans multiple cutting-edge domains, from cancer immunotherapy to neurological disease treatment.
One of her most notable contributions involves the development of engineered T cells for cancer therapy. In a recent study, Dr. Ebrahimi and her colleagues explored an innovative approach to creating “off-the-shelf” allogeneic CAR T cells that would be readily available for broader patient access. Rather than relying on genome editing techniques that raise safety concerns, her team engineered synthetic CD3 subunits containing an endoplasmic reticulum retention signal to suppress T cell receptor expression. The results were remarkable: the engineered CAR T cells retained their cancer-killing function while minimizing the risk of graft-versus-host disease, opening new possibilities for scalable, safer cancer immunotherapies.
Dr. Ebrahimi’s research portfolio also includes important work on hemodialysis patients—a population that faces significant physical and psychological challenges. Her randomized controlled trial involving 48 patients at the Boo Ali Sina Dialysis Center in Shiraz demonstrated that an empowerment program combining individual and group counseling sessions improved self-efficacy, quality of life, blood pressure control, and key laboratory indicators including hemoglobin and hematocrit levels. Such research addresses urgent public health needs in Iran, where kidney disease remains a significant burden, while also contributing to the global evidence base for patient-centered interventions.
Beyond her technical contributions, Dr. Ebrahimi embodies a crucial dimension of Iranian women’s scientific leadership: mentorship. With nearly 500 co-authors collaborating on her publications, she has helped train and inspire a generation of younger researchers, many of whom are women. This multiplier effect—where successful women scientists nurture the next wave of talent—represents perhaps the most sustainable contribution Iranian women are making to the country’s scientific future.
Dr. Soraya Rahmani: Leadership in Biochemistry
In the molecular sciences, where the building blocks of life are analyzed and understood, Dr. Soraya Rahmani has emerged as a leading figure among Iran’s elite female scientists. With more than three decades of experience at Tehran University, Dr. Rahmani has pursued a multi-disciplinary strategy in cancer genetics and tumor biology that reflects the sophistication and breadth of Iranian biomedical research.
Dr. Rahmani’s academic journey included transformative international exposure: she initiated her cancer genetics project on leukemia at the Department of Genetics at the Royal Liverpool Hospital, part of the University of Liverpool. This international training equipped her with advanced methodologies and perspectives that she has since applied to the Iranian context, demonstrating how Iranian women scientists have leveraged global connections even under challenging geopolitical circumstances.
Her research focuses on understanding the molecular mechanisms that drive cancer progression and identifying potential therapeutic targets. In a field where discoveries can literally mean the difference between life and death, Dr. Rahmani’s contributions have helped advance our understanding of how genetic factors influence cancer susceptibility and treatment response. Her work is particularly significant given the rising incidence of various cancers in Iran and the broader Middle East region, where environmental factors, changing lifestyles, and genetic predispositions intersect in complex ways.
Dr. Rahmani’s career also highlights an important dimension of Iranian women’s scientific achievement: longevity and sustained contribution. For 34 years, she has maintained an active research program, supervised graduate students, and contributed to the intellectual infrastructure of Iranian biochemistry. This kind of sustained excellence requires not only technical skill but also institutional support, mentorship networks, and personal resilience—qualities that Iranian women scientists have developed in abundance.
Dr. Sepideh Mirzaei-Varzeghani: A Molecular Biologist’s Fight Against Cancer Drug Resistance
The year 2025 brought renewed international attention to Iranian women scientists, none more prominently than Dr. Sepideh Mirzaei-Varzeghani. In September 2025, this molecular biologist was awarded the Mustafa Prize Medal for Scientists Under 40, a prestigious distinction granted within the biennial Mustafa Science and Technology Festival. She is among the first women recipients of this newly instituted medal, which recognizes young scientists from the Islamic world for outstanding contributions to science and innovation.
Dr. Mirzaei-Varzeghani presently serves as an Assistant Professor of Cell and Developmental Biology at the Science and Research Branch of Islamic Azad University in Tehran. Her research focuses on one of the most vexing problems in oncology: why cancers stop responding to drugs, a phenomenon known as acquired resistance. Many patients initially respond well to chemotherapy or radiotherapy, but over time the cancer becomes resistant and continues to grow. Mirzaei-Varzeghani studies the NF-κB pathway, a key cellular signaling cascade that, when overactive, helps cancer cells survive and resist treatment.
Her award-winning work reveals that non-coding RNAs—including microRNAs, long non-coding RNAs, and circular RNAs—can regulate this pathway in powerful ways. These molecules, once dismissed as useless “junk” RNA, can either turn NF-κB on or off, thereby affecting how cancer cells respond to therapy. Mirzaei-Varzeghani’s findings suggest that combining current cancer drugs with RNA-based therapies could reduce drug resistance and lead to more effective, personalized cancer treatments. This research has profound implications: by understanding how to manipulate non-coding RNAs, clinicians may one day be able to re-sensitize resistant tumors to existing drugs, potentially saving countless lives.
Her achievement in 2025 resonates beyond the laboratory. As a woman under 40 receiving a major science award from the Islamic world, she sends a powerful message to young Iranian girls: a career in molecular oncology is not only possible but can lead to global recognition.
Dr. Sara Pahlavan: Bioengineering a Beating Heart
In the field of regenerative medicine, Dr. Sara Pahlavan has contributed to one of the most ambitious goals in biomedical science: the development of functional bioengineered heart tissue. A specialist in cardiac cell electrophysiology, Dr. Pahlavan is an Assistant Professor and leads cardiovascular research at the Royan Institute—the same premier stem cell research center where Dr. Marzieh Ebrahimi also works. The Royan Institute has become a remarkable hub for Iranian women scientists, demonstrating how institutional support can amplify female talent.
In 2025, Dr. Pahlavan and her research team announced a breakthrough in growing heart tissue in the laboratory. They started with a rat heart from which all original cells had been removed, leaving behind a natural extracellular matrix “framework” or scaffold of the heart. They then added human stem cells capable of differentiating into heart cells. Approximately 60 million cells were placed into the heart framework in stages, using specialized bioreactors to help the cells grow properly. To aid cell attachment and survival, the team added growth factors to different parts of the heart structure.
The results were nothing short of remarkable. The cells remained alive, developed into various types of heart cells (including cardiomyocytes, fibroblasts, and endothelial cells), and after just 12 days, the lab-grown heart tissue began to beat in a coordinated manner. This breakthrough, published in the high-impact scientific journal Biomaterials, helps solve major problems in heart tissue engineering, particularly the challenge of creating thick, vascularized cardiac tissue that can survive and function. It brings scientists closer to creating functional heart tissue for future medical use, with long-term implications for treating patients with severe heart disease who face critical shortages of donor organs.
Dr. Pahlavan has been a faculty member at the Royan Institute since 2017 and currently serves as head of its cardiovascular research group. Her work represents a significant step toward developing implantable bioengineered hearts and demonstrates that Iranian women are at the forefront of one of the most exciting frontiers in medicine.
Dr. Bibi Fatemeh Haqir-Sadat: Nanobiotechnology and Cancer Therapeutics
Dr. Bibi Fatemeh Haqir-Sadat stands out as one of Iran’s leading figures in nanobiotechnology and nanomedicine, with more than a decade of sustained research and innovation. Her career exemplifies the power of international training combined with domestic application. She earned her PhD in Nanobiotechnology from the University of Tehran’s Faculty of New Sciences and Technologies and later obtained a second PhD in Nanomedicine from VU Medical Center (VUMC) in Amsterdam, graduating in 2018.
Her doctoral dissertation at VUMC was recognized as one of the top theses in Europe, an achievement underscored by its unusually high scientific output. While European doctoral research typically yields three to four ISI-indexed publications, Haqir-Sadat’s work resulted in ten peer-reviewed ISI articles. The research culminated in the development of a novel cancer drug candidate, which is expected to reach the production stage following completion of regulatory processes. This drug candidate, based on nano-delivery systems, promises to improve the targeting of cancer cells while reducing systemic toxicity.
Beyond academia, Dr. Haqir-Sadat has been actively involved in technology transfer and the commercialization of scientific innovations. She holds 12 finalized domestic patents, several additional patents under final review, and one US patent application currently in the evaluation stage. Her work on nano-based formulations derived from medicinal plants and active pharmaceutical ingredients has received official knowledge-based certification, leading to the development and approval of multiple knowledge-based products. She has also served as a reviewer for domestic and international scientific journals and has participated in more than 70 national and international research projects. Recognitions such as National Top Technologist, Exemplary PhD Student, and Outstanding University Achievement reflect the breadth of her scientific and technological impact.
Haqir-Sadat’s career demonstrates how Iranian women are not only producing fundamental science but also translating it into tangible products that can reach patients—despite the obstacles of sanctions and limited international partnerships.
Dr. Maria Beyhaghi: Nano-Enabled Therapy for Alzheimer’s Disease
In 2025, Dr. Maria Beyhaghi, CEO of a health-focused knowledge-based company based in Mashhad’s Health Technology Park, was selected as a recipient of the COMSTECH Young Women Researcher Grant. This competitive program, organized by the Standing Committee on Scientific and Technological Cooperation of the Organization of Islamic Cooperation (COMSTECH), aims to support emerging women scientists and foster scientific collaboration across member states. Beyhaghi’s selection highlights the growing recognition of Iranian women’s leadership in applied research.
Dr. Beyhaghi’s research centers on nano-formulated herbal therapeutics, particularly for neurodegenerative disorders. Her company has developed a nano-based dietary supplement designed for the prevention and treatment of Alzheimer’s disease. Initially produced in forms such as lozenges and chewing gum, the product was later reformulated as a syrup to better suit elderly patients. The supplement uses nanoparticles containing natural compounds such as fenchol and quercetin, which are known for their antioxidant and neuroprotective properties. These compounds have been nano-formulated to enhance bioavailability and therapeutic efficacy—a critical improvement, as many plant-derived compounds are poorly absorbed by the body in their natural form.
According to Beyhaghi, the formulation targets genes associated with Alzheimer’s disease. Clinical trials involving 30 Alzheimer’s patients demonstrated improvements in behavioral symptoms, sleep quality, and neurological agitation. Additional findings suggested reductions in hand tremors among Parkinson’s patients, along with decreased anxiety and improved motor control. Beyond neurodegenerative disorders, the nano-formulation has shown potential benefits in preventing oral, esophageal, and gastric cancers, reducing inflammation and allergic responses, regulating blood sugar, strengthening immune function, and supporting cardiovascular health. While classified as a supplementary therapy to be used alongside physician-prescribed medications, the product represents a significant application of nanotechnology in natural medicine.
Dr. Beyhaghi’s work exemplifies the entrepreneurial spirit of Iranian women scientists: she leads a knowledge-based company, translates research into clinical trials, and addresses diseases that affect millions worldwide—all while operating from Mashhad’s Health Technology Park.
Dr. Roja Rahimi: Global Recognition for Iranian Traditional Medicine
Completing the cohort of Iranian women who seized the global limelight in 2025 is Dr. Roja Rahimi, Professor of Traditional Pharmacy at Tehran University of Medical Sciences. She received the 2025 Bionorica Phytoneering Award, an international honor presented by the German pharmaceutical company Bionorica. The award recognizes outstanding research in the development, pharmacodynamics, pharmacokinetics, and clinical application of phytopharmaceuticals (plant-based medicines).
Dr. Rahimi holds a PharmD and a PhD in Traditional Pharmacy and completed her postdoctoral research in the pharmacology of medicinal plants used for gastrointestinal disorders in Iranian traditional medicine. Her work has focused extensively on evaluating the safety, efficacy, and pharmacovigilance of herbal medicines, bridging traditional knowledge with modern scientific standards. In an era of growing interest in integrative medicine, Rahimi’s research provides rigorous evidence for treatments that have been used empirically for centuries.
She has authored more than 200 scientific publications, contributed to and edited multiple book chapters for international publishers, and has been listed among the top one percent of highly cited scientists worldwide in multiple years, including 2015-2017, 2022, and 2024. Rahimi’s work has played a key role in positioning Iranian traditional medicine—a system with roots stretching back to Avicenna and Rhazes—as a credible source of therapeutic innovation. Her 2025 award from a German company underscores that scientific excellence can build bridges across cultural and political divides.
The Broader Ecosystem: Statistics, Policies, and International Recognition
The achievements of these eight women—Drs. Nosrati, Ebrahimi, Rahmani, Mirzaei-Varzeghani, Pahlavan, Haqir-Sadat, Beyhaghi, and Rahimi—do not exist in isolation. They are products of a broader ecosystem that has, over the past four decades, systematically expanded educational opportunities for women and normalized the presence of women in advanced scientific training. The statistical portrait of Iranian women in higher education is truly remarkable.
Women now account for 63 to 64 percent of applicants to Iran’s national university entrance examination, the Konkur, with 608,017 women registering in the first round of 2025 compared to 349,781 men. At the postgraduate level, approximately 58 percent of students in professional doctorate programs are women. Women also constitute a growing proportion of faculty members, making up 34 percent of faculty at medical universities. More than 70 women currently serve as vice presidents, ministers, government spokespersons, and in other senior governmental positions.
In the realm of research, Iranian women are making their mark in terms of both quantity and quality. Women were involved in 24 percent of registered inventions in Iran, a figure significantly higher than the global average of 14 to 17 percent. Female scholars constitute 665 out of 4,818 most-cited researchers in the country, representing more than 13 percent of the total, while 375 Iranian female highly-cited researchers are among the top two percent of researchers worldwide in their fields.
Perhaps most strikingly, Iranian women have achieved these gains despite policies that might have been expected to impede their progress. They have responded to constraints by excelling in fields where their participation remains strong, including medicine, biology, chemistry, pharmacology, and nanotechnology. International recognition has increasingly followed, as the 2025 awards to Mirzaei-Varzeghani (Mustafa Prize), Beyhaghi (COMSTECH grant), and Rahimi (Bionorica Phytoneering Award) demonstrate.
These recognitions build on the legacy of figures like Maryam Mirzakhani, the Iranian mathematician who in 2014 became the first woman to win the Fields Medal—often described as the Nobel Prize of mathematics—for her outstanding contributions to the dynamics and geometry of Riemann surfaces. Mirzakhani remains a transcendent role model for Iranian girls and women, proof that Iranian women can achieve the highest possible recognition in even the most abstract and male-dominated fields.
Challenges and the Road Ahead
No account of Iranian women scientists would be complete without acknowledging the significant challenges they continue to face. International sanctions have severely constrained access to laboratory equipment, scientific journals, and opportunities for international collaboration. Many Iranian researchers must rely on older equipment, limited reagents, and creative workarounds. The brain drain of talented scientists—including many women—to universities abroad represents a substantial loss of human capital.
Within Iran, while educational access has expanded dramatically, the translation of that education into professional leadership remains incomplete. Women hold only a minority of senior academic and research leadership positions, despite constituting the majority of students. Moreover, the cultural expectations placed on women—including primary responsibility for childrearing and domestic labor—can create significant barriers to sustained research productivity. While Iranian law provides generous maternity benefits, the day-to-day realities remain challenging.
Yet these challenges have, in many ways, forged Iranian women scientists into remarkably resilient and resourceful researchers. They have learned to collaborate virtually, to share limited resources, to publish in high-impact journals despite access barriers, and to maintain international connections through scientific diplomacy. The very fact that Iranian women have achieved so much under such constraints is a testament to their determination and talent.
Conclusion
The scientific achievements of women in the Islamic Republic of Iran represent one of the twentieth and twenty-first centuries’ most dramatic quiet revolutions. In less than five decades, Iranian women have moved from the margins of formal education to the forefront of STEM research, achieving participation rates that surpass those in many Western countries. Women like Dr. Vahideh Nosrati in pharmacology, Dr. Marzieh Ebrahimi in clinical medicine, and Dr. Soraya Rahmani in biochemistry have long embodied the highest standards of scientific excellence. In 2025, they were joined by a new cohort—Dr. Sepideh Mirzaei-Varzeghani in molecular oncology, Dr. Sara Pahlavan in cardiac tissue engineering, Dr. Bibi Fatemeh Haqir-Sadat in nanobiotechnology, Dr. Maria Beyhaghi in nano-herbal therapeutics, and Dr. Roja Rahimi in traditional medicine—whose achievements seized global attention and earned prestigious international awards.
These women scientists are not exceptions or anomalies. They are products of a deliberate national investment in education that, whatever its ideological motivations, has produced one of the world’s most gender-balanced scientific workforces. They are also actors in their own right—women who have seized the opportunities available to them, overcome formidable obstacles, and contributed meaningfully to the global scientific enterprise.
As the international community continues to debate questions of gender equity in science, Iranian women scientists offer a compelling case study in what is possible when educational access is prioritized and when women are given—and take—the opportunity to pursue their intellectual passions. Their achievements remind us that scientific excellence can flourish in diverse cultural and political contexts, and that women’s contributions to human knowledge are universal. The laboratories of Tehran, the research centers of Shiraz, the Royan Institute, Mashhad’s Health Technology Park, and universities across Iran are producing knowledge that benefits all of humanity. And at the heart of this scientific renaissance stand the women scientists of Iran—quiet, determined, brilliant, and increasingly, impossible to ignore.
